---
name: I3.3 Management of Histologic HSIL and Negative Surveillance for 1 Year in Those Who Are Concerned About the Potential Effect of Treatment on Future Pregnancy Outcomes (primary HrHPV testing)

externalData:
- resources

data:
- 
  resourceType: Patient
  name: Joanne Smith
  gender: female
  birthDate: 1991-01-01
  extension:
  -
    url: http://hl7.org/fhir/us/core/StructureDefinition/us-core-birthsex
    valueCode: F
- 
  resourceType: DiagnosticReport
  code: LOINC#65753-6 Cervix Pathology biopsy report
  status: final
  conclusionCode:
  - SNOMEDCT#22725004 High-grade squamous intraepithelial lesion (morphologic abnormality)
  effectiveDateTime: 2020-06-01
-
  resourceType: DiagnosticReport
  code: LOINC#65753-6 Cervix Pathology biopsy report
  status: final
  conclusionCode:
  - SNOMEDCT#285836003 Cervical intraepithelial neoplasia grade 1 (disorder)
  effectiveDateTime: 2020-12-01
-
  resourceType: DiagnosticReport
  code: LOINC#21440-3 Human papilloma virus 16+18+31+33+35+45+51+52+56 DNA [Presence] in Cervix by Probe
  status: final
  conclusionCode:
  - SNOMEDCT#787724008 Human papillomavirus deoxyribonucleic acid test negative (finding)
  effectiveDateTime: 2020-12-01
-
  resourceType: DiagnosticReport
  code: LOINC#65753-6 Cervix Pathology biopsy report
  status: final
  conclusionCode:
  - SNOMEDCT#285836003 Cervical intraepithelial neoplasia grade 1 (disorder)
  effectiveDateTime: 2021-06-01
-
  resourceType: DiagnosticReport
  code: LOINC#21440-3 Human papilloma virus 16+18+31+33+35+45+51+52+56 DNA [Presence] in Cervix by Probe
  status: final
  conclusionCode:
  - SNOMEDCT#787724008 Human papillomavirus deoxyribonucleic acid test negative (finding)
  effectiveDateTime: 2021-06-01
- 
  resourceType: Observation
  code: http://OUR-PLACEHOLDER-URL.com#FPCQ Does the patient have future pregnancy concerns related to treatment options?
  status: final
  valueCodeableConcept: SNOMEDCT#373066001 Yes (qualifier value)
  effectiveDateTime: 2021-05-01

results:
  Recommendation:
    short: 'See Details'
    date: '2021-06-02'
    group: 'Managing Histology (I.3)'
    details: 
      - 'Subsequent surveillance with HPV-based testing should occur every year since the patient has demonstrated less than CIN2 and less than ASC-H during surveillance following a histologic unspecified or CIN2 result.'